GLP-1 Prescription Growth 2025: What It Means for UK Patients (October 2026)

01 · The short answer

Is GLP-1 prescribing growing in 2025?

On the NHS, Mounjaro is available, with access phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the primary-care rollout began in June 2025, initially for BMI 40+ with four or more qualifying conditions.⁴⁶

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

02 · Getting treatment

What private access costs and how it works

The Mounjaro pen costs £169.99 per month at the 2.5mg starting dose, and all six doses are in stock. Your first 2.5mg pen costs £129.99 with code FIRST40. Every later order is £25 off the standard price (code DOSE25). Switching to us at a higher dose? The first-order discount applies at any dose; a first 15mg order is £289.99.

Across the UK pharmacies we track, the cheapest and dearest Mounjaro pens are £143.96 and £339.00 per month (checked 11 October 2026). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. A first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. A new customer's first order is £40 less and every later order £25 less.

Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. You can start your free consultation online. Our supply comes through official LillyDirect, so pens are genuine KwikPens.

Related guides: Buy Mounjaro and Are glp 1 prescriptions slowing down 2025.

Related guides: Has glp 1 prescription growth slowed 2025 and Are glp 1 prescriptions still growing in 2025.

03 · GLP-1 and Mounjaro

Is GLP-1 the same as Mounjaro?

Not exactly. GLP-1 is a gut hormone and a class of medicines; Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly. It is licensed in the UK for weight management in adults and for type 2 diabetes, and comes as a KwikPen in six strengths from 2.5mg to 15mg.¹

Tirzepatide activates two receptors, GIP and GLP-1, which helps regulate appetite, slow stomach emptying and improve the body's response to insulin. That dual action distinguishes it from single-action medicines such as semaglutide (Wegovy/Ozempic).¹ Compare options on our GLP-1 prescription weight loss medications page.

04 · What the trials show

What do trials show for tirzepatide?

In SURMOUNT-1, 2,539 adults taking tirzepatide alongside diet and exercise lost on average 15% of body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, versus 3.1% with lifestyle changes alone.² For someone starting at 100 kg, 20.9% is about 21 kg.

These are trial averages; individual results vary, and treatment works alongside a reduced-calorie diet and increased activity, not instead of them. At 72 weeks, 85% on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of body weight.²

05 · Eligibility and safety

Who is Mounjaro licensed for?

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used with a reduced-calorie diet and increased physical activity.¹ A prescriber assesses your BMI, history and current medicines first.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system.¹ Ozempic is semaglutide licensed for type 2 diabetes. It is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label. Stopping Ozempic or any prescribed medicine is a decision to make with your prescriber. Report any side effect through the Yellow Card scheme.¹⁹ Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.